Cancer Biomarkers Market – Global Industry Trends from 2017 to 2024


Posted May 26, 2017 by ravikantdubey

Databridgemarketresearch.com presents new report "Cancer Biomarkers Market – Global Industry Trends from 2017 to 2024”, growing at a CAGR of 12.2% from 2017 to 2024, and is expected to reach USD 27.4 billion by 2024.

 
Global Cancer Biomarkers Market, By Tumor (Breast, Lung, Prostate), By Type (Protein Biomarker, Genetic Biomarkers), By Profiling Technology (Proteomics, Genomics, Imaging, Immunoassay), By Application (Diagnostic, Drug Discovery, Prognostic), By Geography (North America, Europe, Asia-Pacific, South America, Rest of the World) – Industry Trends and Forecast to 2024

The Global Cancer Biomarkers Market has accounted to USD 10.9 billion in 2016, growing at a CAGR of 12.2% from 2017 to 2024, and is expected to reach USD 27.4 billion by 2024.

Based on type, the Cancer Biomarkers Market is broadly split into three segments, namely, protein biomarkers, genetic biomarkers, and other biomarkers (includes viral, cell, and carbohydrate biomarkers).

On the basis of cancer type, the Cancer Biomarkers Market is categorized into breast cancer, lung cancer, colorectal cancer, prostate cancer, cervical cancer, and other cancers (includes melanoma, leukemia, gastric, kidney, liver, and pancreatic cancers).

Based on profiling technology, the market is segmented into omics technologies, imaging technologies, immunoassays, cytogenetics, and bioinformatics.

Request for sample pages: http://databridgemarketresearch.com/reports/global-cancer-biomarkers-market/

Based on geography the global cancer biomarkers market is segmented into 5 geographical regions, North America, Europe, Asia-Pacific, South America and rest of the world. The geographical regions are further segmented into 24 major countries such as U.S. Canada, Mexico, Germany, France, U.K., Belgium, Switzerland, Belgium, Turkey, Japan, China, Singapore, Brazil, India, Russia, South Africa and many others. In 2016, North America is expected to dominate the market with a share of 34.7%, growing at a CAGR of 11.2% in the forecast period 2016 to 2022. The dominance of North America is owing to high incidence of cancers such as breast and lungs, coupled with favorable reimbursement scenarios and highest treatment success rate.

“Read more about the Global Cancer Biomarkers Market”

The major players in this market are turning to strategies such as mergers, acquisition and new product developments as major market strategies to penetrate the market. Some of the major players operating in this market are Abbott Laboratories, DiagnoCure Inc., Affymetrix, Inc., Illumina, Inc., Qiagen N.V., Roche Diagnostics Ltd., Agilent Technologies Inc., Quest Diagnostics Inc., Merck & Co. Inc., Hologic, Inc., Becton Dickinson and Company among others.
About Data Bridge Market Research:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Data Bridge Market Research
Website Global Cancer Biomarkers Market
Phone +1-888-387-2818
Business Address Amanora Chambers, Magarpatta Road, Hadapsar
Pune – 411028
Country India
Categories Health , Manufacturing , Medical
Tags cancer biomarkers , cancer biomarkers market , global cancer biomarkers market
Last Updated May 26, 2017